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Summary Identification of gene products exclusively or abundantly expressed in cancer may yield novel tumour markers. We recently
isolated a number of cDNA clones, including a-prothymosin, from rat hepatocellular carcinoma (HCC) using a subtraction-enhanced display
technique. a-Prothymosin is involved in cell proliferation and is regulated by the oncogene c-myc in vitro. In the present study, we analysed
a-prothymosin gene expression and its correlation with c-mycin patients with HCC, cirrhosis and adenoma and in normal controls. Hepatic a-
prothymosin messenger RNA (mRNA) levels were two- to 9.2-fold higher in tumoral tissues than in adjacent non-tumoral tissues in 14 of 17
patients with HCC, regardless of coexisting cirrhosis and viral hepatitis. No marked difference in a-prothymosin mRNA levels was present
in patients with adenoma and hepatic cirrhosis and in healthy controls. The c-myc mRNA amounts were two- to fivefold increased in 11 of
17 patients with HCC and correlated significantly with those of a-prothymosin (P < 0.001). In situ hybridization revealed that increased a-
prothymosin mRNA was localized in the tumour nodules of the patients with HCC. These data suggest that overexpression of a-prothymosin
in HCC patients, correlated with c-myc, is possibly involved in the tumorigenic process and may be a novel molecular markerfor human HCC.
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With an estimated annual incidence of one million cases, hepato-
cellular carcinoma (HCC) is one of the most common malignan-
cies in humans and causes the death of approximately 250 000
patients per year (Lotze et al, 1993). In high-risk areas, such as
Africa and East Asia, aflatoxin-Bl exposure (Sinha et al, 1988)
and chronic hepatitis B (HBV) or C virus (HCV) infection
(Caselmann, 1995; Sharara et al, 1996) are of main importance,
whereas in low-risk areas the different chronic liver diseases of
toxic, metabolic or infectious aetiology, which eventually result in
cirrhosis, constitute the main risk factors (Johnson and Williams,
1987; Wands and Blum, 1991). Overall, the majority of patients
with HCC have a longstanding history of liver cirrhosis (Johnson
and Williams, 1987). The critical point ofmanagement ofpatients
with HCC is to make an early diagnosis, which may bring1the
5-year survival rate to 68% after surgical resection (Tang et al,
1989). The clinical examination is mainly based on imaging
methods, such as computerized tomography (CT) and real-time
ultrasonography. The problems with these methods are that only
tumours growing to a considerable size can be detected (Colombo
et al, 1991). Serum levels of serum a-fetoprotein, which is a
commonly used HCC marker (Wespic and Kirkpatrick, 1979), can
be normal or only moderately elevated, particularly at the early
stage of HCC (Chen et al, 1984). Therefore, more sensitive and
more specific parameters need to be explored.
Altered gene expression is a common feature ofneoplastic cells,
and the steady-state level of particular transcripts may provide
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information on the differentiation status of the hepatocyte, both
during carcinogenesis and in fully developed tumours (Lasserre
et al, 1992). We have previously reported that, by using the
subtraction-enhanced display technique, a number of cDNA
clones including c-myc, a-tocopherol transfer protein (a-TTJFP),
glutathione-S transferase (GST) and ferritin-H were identified and
shown to be differentially expressed during hepatic carcinogenesis
(Wu et al, 1996, 1997a). We also found that one clone was 100%
similar to rat a-prothymosin and its mRNA expression levels in
HCC were higher than in control rats (Wu et al, 1997b).
The a-prothymosin is an acidic nuclear protein containing 111
amino acids, which was first isolated from rat thymus (Haritos et
al, 1994) and was thought to be associated with regulation of
cellular immunity (Zatz and Goldstein, 1995). However, an
accumulating body of evidence suggests that a-prothymosin is
associated with cell proliferation, although the precise mechanism
remains to be elucidated. Forinstance, a-prothymosin mRNA was
found in proliferating lymphoma and transformed 3T3 fibroblast
cells but not in resting cells (Eschenfeldt and Berger, 1986), and
antisense RNA orsynthetic antisense DNAoligomers ofa-prothy-
mosin were able to inhibit cell division in myeloma cells (Sburlati
et al, 1991). More interestingly, a-prothymosin gene transcription
was shown to be directly regulated by activated c-myc in vitro
(Eilers et al, 1991) via an E-box element localized in the first
intron ofthe a-prothymosin gene (Gaubatz et al, 1994).
The c-myc oncogene has been implicated in malignant progres-
sion in a variety ofhuman tumours (Garte, 1993) and in a number
of experimental animal tumour models, particularly in rat HCC
(Nagy et al, 1988; Chandar et al, 1989; Hsieh et al, 1991).
However, no consistent relationship between overexpression of
ci-prothymosin and c-myc in humans with HCC has been
documented. In this study, we have now established that increased
mRNA levels of a-prothymosin parallel the overexpression of
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Table 1 Clinicopathological features of patients with HCC, adenoma or cirrhosis, and of healthy controls
Case Age (years) Sex Cirrhosis HCV/HBV infection a-Prothymosin mRNA (T/N) c-myc mRNA (T/N)
1 49 M + +/+ 6.8 1.9
2 48 M + +/- 2.7 2.5
3 68 M + +/- 9.2 5.0
4 72 M + -/- 5.0 2.8
5 57 M - -/- 2.8 0.9
6 55 M - -/- 3.0 2.8
7 50 M + -/+ 5.2 3.4
8 43 M - -/+ 0.8 0.9
9 50 M - -/- 4.6 4.1
10 55 M - -/- 1.1 0.9
11 63 M + -/- 2.9 2.1
12 72 M - -/- 4.5 3.0
13 62 M + +/- 1.9 1.8
14 57 F - -/- 2.8 2.4
15 48 M + -/+ 2.6 1.1
16 68 M + -/- 2.4 2.2
17 60 M + -/- 2.3 2.2
18 38 M - -/- 1.1 1.4
19 23 F - ND 0.9 1.2
20 25 F - ND 1.2 1.1
21 55 F - ND 0.9 1.0
22 26 M + -/- 1.8* 1.2*
23 42 M + -/+ 1.1* 1.0*
24 37 F + +/+ 1.5* 1.2*
25 46 F + -- .7* 1.4*
26 30 F + -/+ 1.1* 1.3*
27 49 M + -/+ 1.0* 1.1*
28 42 M - -/-
29 38 M - -/-
30 24 M - -/-
ND, not detected; T/N, ratio of mRNA from tumoral tissue to that from non-tumoral tissue (cases 1-17 are HCC; cases 18-21 are adenoma), which is
standardized by 28S rRNA; values with * are ratios of hepatic a-prothymosin and c-myc mRNA levels in cirrhotic patients (cases 22-27) to the mean values of
three healthy controls (cases 28-30); HCV/HBV, hepatitis C and/or B virus.
c-myc and occur in the majority ofpatients with HCC, irrespective
ofcoexisting cirrhosis or viral hepatitis.
PATIENTS AND METHODS
Tumoral and non-tumoral liver tissue samples used in this investi-
gation were obtained from 17 patients with HCC (with cirrhosis,
n = 10; without cirrhosis, n = 7) and hepatic adenoma (n = 4). In
addition, six patients with only liver cirrhosis and three healthy
controls were also included in the study. None of the patients had
been previously treated for HCC. Clinical information on the
patients and diagnosis are provided in Table 1.
Livertissues were examined by standard histopathological tech-
niques using haematoxylin-eosin (H-E) and reticulin staining on
paraffin-embedded liver sections.
Preparation of RNA and Northern blot analysis
Total RNA was extracted from frozen liver tissue of the above-
mentioned patients by using Trizol according to the vendor's
protocol (Gibco BRL, Breda, The Netherlands). The amount of
RNA was determined by measuring the absorbance at 260 nm, and
RNA quality was confirmed by electrophoresis on an agarose gel
stained with ethidium bromide. Total RNA (10 jg) was separated
on a 1% formaldehyde-agarose gel and transferred to a Hybond-N
nylon membrane (Amersham, Aylesbury, UK), according to stan-
dard procedures (Sambrook et al, 1989). After fixation at 80°C for
2 h, the Northern blots were prehybridized for 2 h at 65°C in
6 x SSC (saline sodium citrate), 5 x Denhardt's solution, 0.5%
sodium dodocyl sulphate (SDS), 100 jig ml-' of herring sperm
DNA. Probes were cDNA fragments ofrat a-prothymosin (0.5 kb)
(Wu et al, 1996) and of human c-myc exon 2 (0.41 kb) and were
labelled according to the hexamer-random-primed method,
following the manufacturer's protocol (Promega, Leiden, The
Netherlands). Membranes were hybridized under the same condi-
tions as stated for prehybridization and afterwards were washed
four times for 15 min with 1 x SSC/0.1% SDS and once with
0.2 x SSC/0.1% SDS at 65°C. The membranes were exposed and
scanned with a Phosphorimager radioanalytical scanning system
(Molecular Dynamics, Sunnyvale, CA, USA) to quantify the
amount of radioactivity of individual bands, which was standard-
ized by the intensity of 28S rRNA scanned with the Eagle Eye II
(Stratagene, La Jolla, CA, USA).
In situ hybridization
In situ hybridization was performed on serial paraffin-embedded
liver sections ofpatients with HCC using the method as described
previously (Wu et al, 1997a). The probes (sense strand as negative
control) used in this study were made from a full-length (1.1 kb)
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Figure 1 Northern blot analysis of 10 jg of total RNA from tumoral tissue
(T) and non-tumoral tissue (N) hybridized with a-prothymosin (ProT) in the
representative patients with HCC and adenoma. The intensity of the bands
was quantified with the Phosphorimager and standardized by comparison to
28S rRNA. Numbers correspond to case numbers in Table 1
rat a-prothymosin cDNA cloned in the pCDNA3 vector
(Invitrogen). Labelling was carried out by the T7 or SP6 RNA
polymerase method using [a-35S]UTP (Amersham) to a specific
activity of 108 c.p.m. ug-1. Afterpretreatment ofthe tissue sections
as described (Wu et al, 1997a), 5 x 104 c.p.m. ,ul- of the labelled
probe resuspended in hybridization mixture was applied to each
section. Hybridization was performed overnight at 52°C. Sections
were washed by gentle shaking in two successive baths of 50%
formamide in 1 x SSC at 520C for 15 min. Sections were then
rinsed twice in 1 x SSC for 10 min and once in 0.1 x SSC for
10 min at room temperature. After dehydration in graded ethanol
containing 0.3 M ammonium acetate, the sections were dipped in
Ilford Nuclear Research Emulsion K-5 (Ilford Photo, Leiden,
The Netherlands). After 5-14 days of exposure, the sections
were developed in Amidol developer (4-hydroxy 1,3-phenylenedi-
ammoniumdichloride) (Merck, Amsterdam, The Netherlands),
fixed in 30% sodium thiosulphate pentahydrate in distilled water
and stained with 0.1% nuclear fast red. All sections were examined
in the dark field under microscopy.
Statistical analysis
Results are expressed as means ± s.d. The differences between
means were analysed with Student's t-test. Correlation ofthe ratio
of tumoral to non-tumoral mRNA levels between ferritin-H and
c-myc was examined by Pearson's correlation coefficient, and the
corresponding P-values were calculated. Significance was defined
as a P-value of< 0.05 (double-sided test).
RESULTS
Expression of a-prothymosin and c-myc in liver tissues
of patients with HCC, adenoma and cirrhosis and of
healthy controls
In order to detect hepatic o-prothymosin mRNA levels of HCC,
adenoma and cirrhosis and the relationship with c-myc, equal
amounts of total RNA were blotted and hybridized with the
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Figure 2 The mRNA levels of c-mycfrom tumoral (T) and non-tumoral (N)
tissues were compared in patients with HCC with (A) or without (B) cirrhosis
and in patients with adenoma (C). As in Figure 1, 28S rRNA was used as
reference. Numbers correspond to case numbers in Table 1
ax-prothymosin and c-myc probe. As shown in Figure 1 and Table
1, ax-prothymosin mRNA levels were two- to 9.2-fold higher in
tumoral tissues in 14 of 17 patients with HCC than those in non-
tumoral counterparts, but no difference was found in patients with
adenoma. In addition, a-prothymosin mRNA was also assessed in
six cirrhotic and three healthy controls. In contrast to tumoral
tissue ofHCC, there was no notable change between cirrhosis and
normal controls as shown in Table 1. In parallel, overexpression of
c-myc was found in 11 of 17 HCC patients with cirrhosis (Figure
2A) and without cirrhosis (Figure 2B) but not in patients with
adenoma (Figure 2C and Table 1). No significant difference in a-
prothymosin and c-myc mRNA levels was found either between
the HCC patients with and without coexisting cirrhosis or between
the HCC patients with and without HBV and/or HCV hepatitis
(Figure 3).
Correlation of mRNA amounts of a-prothymosin and
c-myc
To see whether overexpression of a-prothymosin is associated
with c-myc, mRNA levels of both genes were detected and
compared in 21 individuals with HCC and adenoma. As shown in
Figure 4, there is high correlation between mRNA amounts of
a-prothymosin and c-myc (r = 0.802, P < 0.001).
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Figure 4 Correlation between hepatic a-prothymosin and c-myc mRNA
levels for 21 patients with HCC and adenoma
Figure 3 Relative amounts of a-prothymosin and c-myc mRNA in tumoral
tissue to those in non-tumoral tissue for HCC patients with and without
coexisting liver cirrhosis or HBV/HCV infection (P > 0.1, Student's t-test)
A
Figure 5 Histological appearance with H-E staining and localization of
a-prothymosin mRNA on the liver sections from a representative patient with
HCC. A shows a malignant tumour nodule in the liver surrounded by non-
tumoral tissue as indicated by the arrows. (B) In situ hybridization shows that
overexpressed a-prothymosin mRNA is localized to the malignant nodule of
the liver in contrast to the slight expression in non-tumoral tissue (taken in
the bright field) (bar = 250jgm)
Localization of a-prothymosin mRNA liver tissue of a
patient with HCC
To study the tissue distribution of overexpressed a-prothymosin
mRNA, an antisense RNA probe was radiolabelled and hybridized
on liver sections. A high level a-prothymosin mRNA expression
was present in neoplastic nodules confirmed by H-E staining
(Figure 5A) compared with the slight expression in non-tumour
liver tissue as indicated by the arrowheads (Figure 5B), whereas
no specific mRNA was detectable using sense-stranded a-pro-
thymosin RNA probe (data not shown).
DISCUSSION
a-Prothymosin, a cellularproliferation-associated gene, is elevated
in malignant cells and tissues compared with healthy ones
(Dominguez et al, 1993). In this study, we showed that hepatic
mRNA levels of a-prothymosin were significantly higher in the
tumoral tissues than those in the corresponding non-tumoral
tissues in 14 of 17 patients with HCC, irrespective of coexisting
cirrhosis or HBV and/or HCV hepatitis. No difference in
a-prothymosin mRNA levels was found in patients with adenoma,
a benign liver tumour. Moreover, in situ hybridization revealed
that overexpressed a-prothymosin mRNA was localized in the
malignant tumour nodules. Together with our recent finding that
overexpression of a-prothymosin is restricted to well-defined
tumour nodules and to vaso-invading cancer cells in rat HCC
rather than to non-tumour regeneration nodules (Wu et al, 1997b),
these data suggestthat the enhanced transcription ofa-prothymosin
is associated with HCC.
As other evidence supports the view that a-prothymosin is
involved in cellular proliferation (Eschenfeldt and Berger, 1986;
Eilers et al, 1991; Sburlati et al, 1991), we considered the possi-
bility that overexpression of a-prothymosin might be due to
benign liver regeneration nodules that may coexist in HCC tissue.
To test this possibility, we have studied mRNA levels ofa-prothy-
mosin in patients with only cirrhosis and in healthy controls. No
significant difference was found between patients with cirrhosis
and controls, suggesting that enhanced transcription of a-prothy-
mosin is specifically related to HCC.
The exact mechanism underlying the overexpression of
a-prothymosin during carcinogenesis is unknown. A correlation of
enhanced a-prothymosin mRNA to c-myc has been shown in
patients with breast cancer (Dominguez et al, 1993) and colon
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cancer (Mori et al, 1993). Proto-oncogenes like c-myc play an
important role in the multiple process ofcarcinogenesis (Land et al,
1983), including HCC (Nagy et al, 1988; Gan et al, 1993). For
instance, c-myc MMA levels are enhanced in patients with HCC
(Gan et al, 1993; Garte, 1993). Here, we analysed the correlation
between a-prothymosin and c-myc expression in the patients with
HCC and found that mRNA levels ofboth genes were highly corre-
lated. Although the evidence is indirect, our results support the
finding reported by Eilers and co-workers (1991) in their in vitro
study that a-prothymosin expression is under the regulation of the
c-myc gene (Gaubatz et al, 1994), although there is a conflicting
report that Myc in vitro fails to activate transcription of the intact
human prothymosin alpha gene orreporter constructs that mimic its
structure (Mol et al, 1995). Three patients with HCC in this study
showed mRNA levels of x-prothymosin to be inconsistent with
those ofc-myc, suggesting that alternative regulation may exist. For
instance, it has recently been shown in vitro that the transcription
factor E2F is a strong positive regulator ofa-prothymosin through
the promoterregion ofthe gene (Vareli et al, 1996), and the deregu-
lation of E2F activity is thought to contribute to the uncontrolled
proliferation of many tumour cells. While the effects of overex-
pressing E2F genes have been studied in tissue culture, the conse-
quences of elevating E2F activity in vivo are unknown (Du et al,
1996). We believe that an extended investigation ofthe association
ofE2F and a-prothymosin in HCC patients would be interesting.
In addition, in the remaining three patients with HCC who did
not show significant high levels in the a-prothymosin mRNA, no
concrete differences in terms of sex, age, viral hepatitis or liver
cirrhosis were observed. But the limited number of patients does
not allow any firm conclusion in this report. However, the present
data illustrate the complexity of hepatic carcinogenesis in which
multiple factors are involved (Anthony, 1994).
Of interest is the question whether overexpression of
a-prothymosin is a specific feature of malignancy (Dominguez et
al, 1993). Our data show that the enhanced a-prothymosin mRNA
detected in 82% of patients with HCC is independent of liver
cirrhosis or viral hepatitis, which are widely believed to be precan-
cerous diseases of human HCC (Aihara et al, 1996). The results
favour the interpretation that the elevated a-prothymosin is associ-
ated with human HCC and that it probably acts as a sensitive indi-
cator ofuncontrolled liver cell proliferation.
In summary, we conclude that a-prothymosin mRNA levels are
increased in 82% of patients with HCC regardless of coexisting
liver cirrhosis or viral hepatitis and are correlated with c-myc.
a-Prothymosin may be a novel molecular marker for HCC.
ABBREVIATIONS
mRNA, messenger RNA; HCC, hepatocellular carcinoma;
HBV/HCV, hepatitis B and/or C virus
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